Literature DB >> 11591560

Effect of acute myocardial infarction on cholesterol ratios.

N Wattanasuwan1, I A Khan, R M Gowda, B C Vasavada, T J Sacchi.   

Abstract

OBJECTIVE: In patients with acute myocardial infarctions (MIs), cholesterol levels are no longer valid after 24 h from presentation because acute MI causes a rapid decline in serum levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. The objective of this study was to evaluate the effect of acute MI on the total cholesterol/HDL cholesterol ratio and the LDL cholesterol/HDL cholesterol ratio.
METHODS: The study consisted of 45 patients who were admitted to the hospital with acute MIs. Serum levels of total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were determined on day 1 post-MI and day 4 post-MI. The total cholesterol/HDL cholesterol ratio and the LDL cholesterol/HDL cholesterol ratio were calculated. Serum lipid levels and cholesterol ratios were compared between day 1 post-MI and day 4 post-MI.
RESULTS: From day 1 post-MI to day 4 post-MI, the mean (+/- SD) serum levels of total cholesterol (188.4 +/- 52.5 vs. 170.5 +/- 57.2 mg/dL, respectively; p = 0.01), LDL cholesterol (120.3 +/- 48.9 vs. 105.9 +/- 43.0 mg/dL, respectively; p = 0.009), and HDL cholesterol (45.0 +/- 18.5 vs 39.3 +/- 16.1 mg/dL, respectively; p < 0.001) decreased, but the mean serum level of triglycerides (119.2 +/- 81.2 vs 149.3 +/- 68.3 mg/dL, respectively; p = 0.006) increased. The cholesterol ratios, however, remained unchanged between day 1 post-MI and day 4 post-MI. The total cholesterol/HDL cholesterol ratio was 4.59 +/- 1.84 on day 1 post-MI and 4.67 +/- 1.77 on day 4 post-MI (change not significant). The LDL cholesterol/HDL cholesterol ratio was 2.96 +/- 1.58 on day 1 post-MI and 2.99 +/- 1.44 on day 4 post-MI (change not significant).
CONCLUSION: Acute MI does not affect the cholesterol ratios. Therefore, when the absolute levels of serum cholesterol are no longer valid (beyond 24 h after an MI), the cholesterol ratios still could be useful for cholesterol risk assessment in patients with acute MIs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11591560     DOI: 10.1378/chest.120.4.1196

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

1.  Prevalence of Achilles tendon xanthoma and familial hypercholesterolemia in patients with coronary artery disease undergoing percutaneous coronary intervention.

Authors:  Hideki Kitahara; Naoto Mori; Yuichi Saito; Takashi Nakayama; Yoshihide Fujimoto; Yoshio Kobayashi
Journal:  Heart Vessels       Date:  2019-04-09       Impact factor: 2.037

2.  Influence of ApoB100 3' hypervariable repeats on acute myocardial infarction.

Authors:  Neha Singh; Nakul Sinha; Sudeep Kumar; Chandra M Pandey; Suraksha Agrawal
Journal:  Heart Asia       Date:  2014-11-07

3.  Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes.

Authors:  Li Song; Xiaoxiao Zhao; Runzhen Chen; Jiannan Li; Jinying Zhou; Chen Liu; Peng Zhou; Ying Wang; Yi Chen; Hanjun Zhao; Hongbing Yan
Journal:  Cardiovasc Diabetol       Date:  2022-05-20       Impact factor: 8.949

4.  Association of low-density lipoprotein pattern with mortality after myocardial infarction: Insights from the TRIUMPH study.

Authors:  Yashashwi Pokharel; Yuanyuan Tang; Bhaskar Bhardwaj; Krishna K Patel; Mohammed Qintar; James H O'Keefe; Krishnaji R Kulkarni; Peter H Jones; Seth S Martin; Salim S Virani; John A Spertus
Journal:  J Clin Lipidol       Date:  2017-10-03       Impact factor: 4.766

5.  The Myocardial Ischemia Reduction with Acute Cholesterol Lowering trial: MIRACuLous or not, it's time to change current practice.

Authors:  Herbert D Aronow
Journal:  Curr Control Trials Cardiovasc Med       Date:  2002-01-07

6.  Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies.

Authors:  Naif A M Almontashiri; Ragnar O Vilmundarson; Nima Ghasemzadeh; Sonny Dandona; Robert Roberts; Arshed A Quyyumi; Hsiao-Huei Chen; Alexandre F R Stewart
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

7.  Glucose-6-phosphate dehydrogenase deficiency protects against coronary heart disease.

Authors:  L Meloni; M R Manca; I Loddo; G Cioglia; P Cocco; A Schwartz; S Muntoni; Sa Muntoni
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.750

8.  Mendelian randomization of blood lipids for coronary heart disease.

Authors:  Michael V Holmes; Folkert W Asselbergs; Tom M Palmer; Fotios Drenos; Matthew B Lanktree; Christopher P Nelson; Caroline E Dale; Sandosh Padmanabhan; Chris Finan; Daniel I Swerdlow; Vinicius Tragante; Erik P A van Iperen; Suthesh Sivapalaratnam; Sonia Shah; Clara C Elbers; Tina Shah; Jorgen Engmann; Claudia Giambartolomei; Jon White; Delilah Zabaneh; Reecha Sofat; Stela McLachlan; Pieter A Doevendans; Anthony J Balmforth; Alistair S Hall; Kari E North; Berta Almoguera; Ron C Hoogeveen; Mary Cushman; Myriam Fornage; Sanjay R Patel; Susan Redline; David S Siscovick; Michael Y Tsai; Konrad J Karczewski; Marten H Hofker; W Monique Verschuren; Michiel L Bots; Yvonne T van der Schouw; Olle Melander; Anna F Dominiczak; Richard Morris; Yoav Ben-Shlomo; Jackie Price; Meena Kumari; Jens Baumert; Annette Peters; Barbara Thorand; Wolfgang Koenig; Tom R Gaunt; Steve E Humphries; Robert Clarke; Hugh Watkins; Martin Farrall; James G Wilson; Stephen S Rich; Paul I W de Bakker; Leslie A Lange; George Davey Smith; Alex P Reiner; Philippa J Talmud; Mika Kivimäki; Debbie A Lawlor; Frank Dudbridge; Nilesh J Samani; Brendan J Keating; Aroon D Hingorani; Juan P Casas
Journal:  Eur Heart J       Date:  2014-01-27       Impact factor: 29.983

9.  Serial measurement of lipid profile and inflammatory markers in patients with acute myocardial infarction.

Authors:  Amit Kumar Shrivastava; Harsh Vardhan Singh; Arun Raizada; Sanjeev Kumar Singh
Journal:  EXCLI J       Date:  2015-04-10       Impact factor: 4.068

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.